Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
November 10 2022 - 9:05AM
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:
CLLS), a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, today announced that preclinical data will be presented
on TALEN®-edited smart CAR T-cells overcoming key challenges of
targeting solid tumors at the Society for Immunotherapy of Cancer’s
(SITC) 37th Annual Meeting.
The data will be presented today in two poster sessions titled:
“Multi-armored allogeneic MUC-1 CAR T-cells efficiently control
triple negative breast cancer tumor growth”
(Poster Number:
217) and “TALEN®-edited smart CAR T-cells leverage
solid tumor microenvironment for specific and effective
immunotherapy” (Poster Number:
325).
The poster presentations highlight the following preclinical
data:
Multi-armored allogeneic MUC-1 CAR T-cells efficiently
control triple negative breast cancer tumor growth
- This poster
highlights TALEN®-edited smart CAR T-cells targeting MUC1-
expressing solid tumors.
- MUC1 is a
tumor-associated antigen that is overexpressed in triple-negative
breast cancer (TNBC) and other solid tumor malignancies.
- MUC-1 CAR T-cells
infiltrate tumors more efficiently and extend survival when
enhanced with attributes catered towards the tumor microenvironment
(TME) of TNBC tumors.
- TGFBR2 knock-out
(KO) circumvents the inhibitory effects of TGFβ1, and IL-12 release
follows CAR T-cell activation pattern restricting it to the tumor
site for increased safety.
- Enhanced MUC-1 CAR
T-cells could address some of the current challenges in development
of CAR Ts for TNBC patients with unmet medical needs.
- Overall, we can
efficiently generate allogeneic CAR T-cells and engineer them to
overcome several key challenges of immune suppressive solid
tumors.
TALEN®-edited smart CAR T-cells leverage solid tumor
microenvironment for specific and effective
immunotherapy
-
This poster highlights innovative T-cell engineering strategies
designed to increase the activity of CAR T-cells for solid tumors
while mitigating toxicity risk.
- Therapeutic efficacy
of CAR T-cell therapy has so far been restricted to only a few
malignancies, with solid tumors proving to be especially
recalcitrant to efficient therapy. Our TALEN®-based gene editing
platform allows innovative T cell engineering strategies that can
combat some of the challenges posed by CAR T cell development for
solid tumors.
-
Inducible expression of a tumor-antigen directed CAR by a
constitutive CAR specific to TME cues greatly enhanced anti-tumor
activity, while limiting ‘on target, off-tumor’ cytotoxicity.
Additionally, CAR-induced gene expression could boost anti-tumor
CART only within the TME.
- Cellectis’ gene
editing strategies could increase CAR T cell persistence and
anti-tumor activity while staying restricted to the tumor
milieu.
- This proof-of-concept study demonstrates the feasibility of
developing CART cell engineering strategies that can improve solid
tumor targeting while mitigating potential safety risks, paving the
way for clinical development.
Laurent Poirot, Ph.D., Senior Vice President Immunology at
Cellectis, noted:
“Using our TALEN®-based gene editing platform,
we have presented innovative T cell engineering strategies that can
combat some of the challenges posed by CAR T cell development for
solid tumors. We are mitigating potential safety risks, paving the
way for clinical development for patients with unmet medical
needs.”
Presentations will occur today, from 9:00AM until 9:00PM ET,
Hall C.
A copy of both poster presentations will be available on
Cellectis’ website here, shortly after the event.
About CellectisCellectis is a
clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies. Cellectis utilizes an allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to make therapeutic gene editing in
hemopoietic stem cells for various diseases. As a clinical-stage
biopharmaceutical company with over 22 years of experience and
expertise in gene editing, Cellectis is developing life-changing
product candidates utilizing TALEN®, its gene editing technology,
and PulseAgile, its pioneering electroporation system to harness
the power of the immune system in order to treat diseases with
unmet medical needs. Cellectis’ headquarters are in Paris, France,
with locations in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and
on Euronext Growth (ticker: ALCLS).
For more information, visit www.cellectis.com.
Follow Cellectis on social media: @cellectis, LinkedIn and
YouTube.
For further information, please
contact:
Media contacts: Pascalyne
Wilson, Director, Communications, +33 (0)7 76 99 14
33, media@cellectis.com Margaret Gandolfo, Senior Manager,
Communications, +1 (646) 628 0300
Investor Relation contact: Arthur
Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com Ashley R. Robinson, LifeSci
Advisors, +1 617 430 7577
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,”
“could,” “may” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management. Forward-looking
statements include statements about the potential of our
preclinical programs and product candidates. These forward-looking
statements are made in light of information currently available to
us and are subject to numerous risks and uncertainties, including
with respect to the numerous risks associated with
biopharmaceutical product candidate development. With respect to
our cash runway, our operating plans, including product development
plans, may change as a result of various factors, including factors
currently unknown to us. Furthermore, many other important factors,
including those described in our Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2021 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time, as well as
other known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our actual
results, performance or achievements to be materially different
from those expressed or implied by the forward-looking statements.
Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Oct 2023 to Oct 2024